Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation

American Journal of Transplantation

Volumn 4, Issue 7, 2004, Pages 1079-1083

  Kiberd, Bryce A ^a   Lawen, Joseph ^a   Fraser, Albert D ^a   Keough Ryan, Tammy ^a   Belitsky, Philip ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Absorption profile monitoring; Cyclosporine; Mycophenolate mofetil; Pharmacodynamics; Pharmacokinetics; Rejection; Therapeutic drug monitoring

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOPENIA; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; SURGICAL PATIENT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 3042743984     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00455.x     Document Type: Article

References (20)

1. Belitsky P. Neoral use in the renal transplant recipient. Transplant Proc 2003; 32: 10-19.
2. Clase CM, Mahalati K, Kiberd BA et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002; 2: 789-95.
3. Mahalati K, Belitsky P, West K et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 2001; 12: 828-833.
4. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States: 1988-96. N Engl J Med 2000; 342: 605-612.
5. Weber LT, Shipkova M, Armstrong VW et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german Study Group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13: 759-768.
6. van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261-266.
7. Hale MD, Nicholls AJ, Bullingham RES et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Trials Ther 1998; 64: 672-683.
8. Shaw LM, Holt DW, Oellerich M, Meiser B, Van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305-315.
9. Cox VC, Ensom MHH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003; 25: 137-157.
10. Nicol DL, MacDonald AS, Belitsky P et al. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients. Transplantation 1993; 55: 841-846.
11. Yeung S, Tong KL, Tsang WK et al. Determination of mycophenolate area under the curve by limited sampling strategy. Transplant Proc 2001; 33: 1052-1053.
12. Svensson J-O, Braltstrum C, Sawe J. A simple method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Ther Drug Monit 1999; 21: 322-324.
13. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
14. Balbontin F, Kiberd B, Singh D et al. Basiliximab widens the therapeutic window for AUC-monitored neoral therapy early after kidney transplantation. Transplant Proc 2003; 35: 2409-2411.
15. Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation, past, present, and future. Semin Nephrol 2000; 20: 108-125.
16. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients, a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39-47.
17. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381-2386.
18. Dresske B, Zavazava N, Jenisch S et al. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation. Transplantation 2003; 75: 1286-1291.
19. Quemeneur L, Flacher M, Gerland LM, French M, Revillard JP, Bonnefoy-Berard N. Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis. J Immunol 2002; 169: 2747-2755.
20. Baan CC, Balk AH, van Riemsdijk IC et al. Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation. Transplantation 2003; 75: 1704-1710.